Skip to main content

Susan Halabi CV

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2717, Durham, NC 27710
2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
CV

Selected Grants


Research Triangle Center of Excellence in Regulatory Science and Innovation

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era

ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026

Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2021 - 2026

Defining clinically actionable subtypes of castration-resistant prostate cancer through epigenetic cell-free DNA analysis

ResearchPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2023 - 2026

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer

ResearchCo Investigator · Awarded by University of Wisconsin - Madison · 2023 - 2026

Sieve spline based likelihood approach for the Cox proportional hazards model with small sample size studies

ResearchCo-Principal Investigator · Awarded by National Cancer Institute · 2023 - 2026

Statistical Methods and Validation Analyses for the Integration of Real-World

ResearchPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2021 - 2025

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2020 - 2025

Targeting neuroendocrine cells in prostate cancer with small molecule and targeted radionuclide therapies

ResearchCo Investigator · Awarded by Prostate Cancer Foundation · 2023 - 2025

HERO Program, HERO Registry, HERO-HCQ Trial

Clinical TrialStatistical Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2020 - 2025

Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer

ResearchPrincipal Investigator · Awarded by Prostate Cancer Foundation · 2018 - 2025

Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025

PARPi Response Evaluation for Clinical Impact and Scientific Innovation in Oncology: The PRECISION Registry

ResearchPrincipal Investigator · Awarded by Yale University · 2023 - 2024

Development of a Clinical Genomic Model in Metastatic Castration Resistant Prostate Cancer

ResearchPrincipal Investigator · Awarded by University of Michigan · 2022 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

HOXB13 as a therapeutic target in prostate cancer

ResearchStatistician · Awarded by Prostate Cancer Foundation · 2020 - 2024

Prognostic Model of Overall Survival in Bladder Cancer

ResearchPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2021 - 2023

Interactions of Androgen Production, Uptake and Metabolism on outcome in CRPC

ResearchPrincipal Investigator · Awarded by University of Minnesota · 2021 - 2023

PROPHECY CTC PSMA Project

ResearchPrincipal Investigator · Awarded by Epic Sciences, Inc · 2022 - 2022

Precision Medicine in Platinum-treated Lethal Bladder Cancer

ResearchPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2017 - 2022

PARPi Response Evaluation for Clinical Impact and Scientific Innovation in Oncology: The PRECISION Registry

ResearchPrincipal Investigator · Awarded by Thomas Jefferson University · 2022 - 2022

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

ResearchPrincipal Investigator · Awarded by Department of Defense · 2018 - 2022

Translational Research in Surgical Oncology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2002 - 2022

Role of oncogenic phosphorylated MED1 in aggressive prostate cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2022

Statistical Analysis of CTC enumeration and neuroendocrine cell features in the PROPHECY trial (NCT02269982)

ResearchPrincipal Investigator · Awarded by Epic Sciences, Inc · 2020 - 2020

Serum Androgens and Survival in CRPC

ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2015 - 2018

Optimizing First Line Treatment for Men with Castrate Resistant Prostate Cancer

ResearchPrincipal Investigator · Awarded by Prostate Cancer Foundation · 2015 - 2018

National Clinical Trials Network - Network Group Statistics and DMCs

ResearchStatistician · Awarded by Mayo Clinic · 2014 - 2017

Validation of prognostic and pathway signatures in lethal prostate cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2017

Developing and Validating Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2016

Expression Profiling of Renal Cell Carcinoma Utilizing Tissue from CALGB 90206

ResearchPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2012 - 2015

Predictive Markers in Metastatic Renal Cancer

ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2013 - 2014

Cancer and Leukemia Group B Statistical Center

ResearchStatistician · Awarded by National Institutes of Health · 1982 - 2010

Telomerase RNA Transfected Dendritic Cell Vaccines

Clinical TrialStatistician · Awarded by National Institutes of Health · 2002 - 2006

External Relationships


  • Aveo Oncology
  • Bristol-Myers Squibb (BMS)
  • CG Oncology
  • Janssen Oncology
  • Sanofi

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.